Therapy Areas: Infectious Diseases
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
17 April 2024 - Biopharmaceutical company GSK (LSE/NYSE: GSK) on Wednesday declared promising EAGLE-1 phase III trial results for gepotidacin, a potential breakthrough oral antibiotic targeting uncomp...
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
12 April 2024 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the company), a late-stage biopharmaceutical company, announced on Thursday that it has received orphan drug designation for the active ing...
YS Biopharma repays USD40m loan facility
3 April 2024 - Biopharmaceutical company YS Biopharma Co, Ltd (Nasdaq: YS) on Wednesday declared the full repayment of a USD40m loan facility borrowed under an agreement dated 16 March 2022. The repay...
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
26 March 2024 - Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compar...
Scancell initiates SCOPE trial's iSCIB1+ cohort
26 March 2024 - Scancell Holdings plc (AIM: SCLP), a clinical stage biopharmaceutical company, reported on Tuesday that it has dosed the first patient with iSCIB1+ and doublet checkpoint inhibitor the...
BioVaxys Technology announces non-brokered private placement
25 March 2024 - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF), a biopharmaceutical company registered in British Columbia, Canada, announced on Friday that it planning to complete a ...